Abstract
Population pharmacokinetic-dynamic analysiswas prospectively integrated in a broadphase II program of lurtotecan (GI147211),a novel camptothecin derived topoisomeraseI inhibitor, to determine the populationpharmacokinetic profile in a largerpopulation, to estimate individualpharmacokinetic parameters and toinvestigate relationships with clinicaloutcome. A sparse sampling method wasapplied during course one, which involvedtwo sampling time-points. A Bayesianalgorithm was used to estimate individualpharmacokinetic parameters, in particulartotal plasma clearance (CL) and volume ofdistribution. In total, samples werecollected of 109 (63%) of 173 patients.Pharmacokinetic-dynamic evaluation could becarried out successfully in 85 (78%) ofthe sampled patients. CL of lurtotecanshowed substantial variability (mean 87± 28 L/h) and was of the same magnitudeas in the phase I studies where fullpharmacokinetic curves were used. Residualvariability in the population estimate ofCL was 9.9%. No significant relationshipswere observed between exposure parametersand toxicity nor likelihood of tumorresponse, however the latter relationshipmay well have been obscured by theheterogeneity of the studied population.Prospective implementation of large scalepopulation pharmacokinetic-dynamic analysisis feasible and important to establishwhether interpatient variability in drugexposure is a major determinant of toxicityor activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Liu LF: DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 58: 351–375, 1989
Wang JC, Liu LF: In: Cozzarelli NR, Wang JC, eds. DNA topology and its biological effects. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1990
Potmesil M: Camptothecins: from bench research to hospital wards. Cancer Res 54: 1431–1439, 1994
Stewart L, Redinbo MR, Qiu X, Hol WGJ, Champoux JJ: A model for the mechanism of human topoisomerase I. Science 279: 1534–1541, 1998
Ryan AJ, Squires S, Strutt HL, Johnson RT: Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 19: 3295–3300, 1991
Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G, Kohn KW: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Investig 12: 430–542, 1994
Rothenberg ML: Topoisomerase I inhibitors: review and update. Ann Oncol 8: 837–855, 1997
Schellens JHM, Pronk LC, Verweij J: Emerging drug treatments for solid tumours. Drugs 51: 45–72, 1996
Gerrits CJH, Creemers GJ, Schellens JHM, Wissel P, Planting AST, Kunka R, Selinger K, de Boer-Dennert M, Marijnen Y, Harteveld M, Verweij J: Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily ×5 intravenous administration. Br J Cancer 73: 744–750, 1996
Eckhardt SG, Baker SD, Eckhardt JR, Burke TG, Warner DL, Kuhn JG, Rodriguez G, Fields S, Thurman A, Smith L, Rothenberg ML, White L, Wissel P, Kunka R, Littlefield D, Burris HA, Von Hoff D, Rowinsky EK: Phase I and pharmacokinetic study of GF147211, a water-soluble camptothecin analogue administered five consecutive days every three weeks. Clin Cancer Res 4: 595–604, 1998
Gerrits CJH, Schellens JHM, Creemers GJ, Wissel P, Planting AST, Pritchard JF, DePee S, de Boer-Dennert M, Harteveld M, Verweij J: The bioavailability of oral GI146211 (GG211), a new topoisomerase I inhibitor. Br J Cancer 76: 946–951, 1997
Sheiner LB, Benet LZ: Premarketing observational studies of population pharmacokinetics of new drugs. Clin Pharmacol Ther 38: 481–487, 1985
Rowland M, Aarons L (eds): New strategies in drug development and clinical evaluation: The population approach. Brussels, Belgium, Commission of European Communities, 1992
Peck CC, Barr WH, Bennet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH: Conference report: Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. Clin Pharmacol Ther 51: 465–473, 1992
Vozeh S, Steimer JL, Rowland M, Morselli P, Mentre F, Balant L, Aarons L: The use of population pharmacokinetics in drug development. Clin Pharmacokinet 30: 81–93, 1996
Launay-Iliadia MC, Bruno R, Cosson V, Vergniol JC, Oulid-Aissa D, Marty M, Clavel M, Aapro M, le Bail N, Iliadia A: Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum likelihood estimation. Cancer Chemother Pharmacol 37: 47–54, 1995
Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinink WW, van Oosterom AT, Kay SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB: Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187–196, 1998
Urien S, Barré J, Morin C, Paccaly A, Montay G, Tillement JP: Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein. Invest New Drug 14: 147–151, 1996
Stafford CG, St Claire III RL: High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma. J Chromatogr 663: 119–126, 1995
Sheiner LB, Beal SL: Some suggestions for measuring predictive performance. J Pharmacokinet Biopharmaceut 9: 503–512, 1981
Beal SL, Boeckman AJ, Sheiner LB: NONMEM. User's guide part I to VI. San Francisco, CA, University of California at San Francisco, 1988–1992
Holford NH, Sheiner LB: Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6: 242–247, 1981
Hashimoto Y, Sheiner LB: Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. J Pharmacokinet Biophar 19: 333–335, 1991
Sheiner LB, Ludden TM: Population pharmacokinetics/dynamics. Ann Rev Pharmacol Toxicol 32: 185–190, 1992
Creemers GJ, Gerrits CJH, Eckardt JR, Schellens JHM, Burris HA, Planting AST, Rodriguez GI, Loos WJ, Hudson I, Broom C, Verweij J, Von Hoff DD: Phase I and pharmacologic study of oral topotecan administered twice daily for 21-days to adult patients with solid tumors. J Clin Oncol 15: 1087–1093, 1997
Van Warmerdam LJC, Verweij J, Schellens JHM, Rosing H, Davies BE, De Boer-Dennert M, Maes RAA, Beijnen JH: Pharmacokinetics and pharmacodynamics of topotecan administered in a daily times five regimen every three weeks. Cancer Chemother Pharmacol 35: 237–245, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schellens, J., Heinrich, B., Lehnert, M. et al. Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies. Invest New Drugs 20, 83–93 (2002). https://doi.org/10.1023/A:1014454821885
Issue Date:
DOI: https://doi.org/10.1023/A:1014454821885